Exceptional surveillance of early and locally advanced breast cancer: diagnosis and management (NICE guideline NG101)

In 2022 NICE published an exceptional review to examine any impact on NICE's guideline on early and locally advanced breast cancer of published evidence on the indications for using adjuvant bisphosphonates in people with early and locally advanced breast cancer

Classifications: Adjuvant & Neoadjuvant Treatment

Keywords: Bisphosphonates